Premium
Developments in Clinical Islet, Liver Thoracic, Kidney and Pancreas Transplantation in the Last 5 Years
Author(s) -
Feng S.,
Barr M.,
Roberts J.,
Oberbauer R.,
Kaplan B.
Publication year - 2006
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2006.01402.x
Subject(s) - medicine , transplantation , liver transplantation , intensive care medicine , pancreas transplantation , liver disease , diabetes mellitus , economic shortage , pancreas , immunosuppression , organ transplantation , surgery , kidney transplantation , endocrinology , linguistics , philosophy , government (linguistics)
Although organ transplantation has matured into a proven therapy for end‐stage organ failure, the many notable developments of the past 5 years speak to the multitude of remaining challenges. Two new procedures, islet transplantation and adult‐to‐adult living donor liver transplantation, have emerged to enlarge our therapeutic armamentarium for Type 1 diabetes mellitus and end‐stage liver disease, respectively. In cardiac transplantation, the acceptance of ventricular assist devices as destination therapy is a notable event in light of critical shortage of deceased donor organs. Both liver and lung allocation policies have made a dramatic paradigm shift away from waiting time toward the survival benefit of transplantation. Finally, primary threats to post‐transplant longevity have gained an increasing share of the spotlight. Recognition of the impact of renal insufficiency for all nonrenal transplant recipients, of recurrent hepatitis C virus for liver recipients, and of accelerated vasculopathy for cardiac have identified novel end points for clinical trials.